Cas13-Mediated RNA Base Editing for the Treatment of Hereditary Hypertrophic Cardiomyopathy

Affiliations

• ¹ Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China (Q.H., H.C., X.Z., S.W., M.D., B.W., T.L., X.G., Q.H., Y.L., S.L., H.Y., H.-B.-L., G.L.).
• ² Department of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China (J.L.).
• ³ State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine & School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China (H.C., H.-B.L.).
• ⁴ HuidaGene Therapeutics Inc, Shanghai, China (M.W., H.Y., G.L.).
• ⁵ Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China (H.Y., G.L.).
• ⁶ State Key Laboratory of Chemical Biology, Shanghai Institute of Materia, Medica, Chinese Academy of Sciences, China (H.-B.L.).
• ⁷ University of Chinese Academy of Sciences, Beijing, China (H.-B.L.).